The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
The RESTORE Study
Open accessAbstract
OBJECTIVE: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). DESIGN: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. PARTICIPANTS: We included 345 patients aged ≥18 years, with type 1 or 2 diabetes mellitus and visual impairment due to DME. METHODS: Patients were randomized to ranibizumab + sham laser (n = 116), ranibizumab + laser (n = 118), or sham injections + laser (n = 111). Ranibizumab/sham was given for 3 months then pro re nata (PRN); laser/sham laser was given at baseline then PRN (patients had scheduled monthly visits). MAIN OUTCOME MEASURES: Mean average change in BCVA from baseline to month 1 through 12 and safety. RESULTS: Ranibizumab alone and combined with laser were superior to laser monotherapy in improving mean average change in BCVA letter score from baseline to month 1 through 12 (+6.1 and +5.9 vs +0.8; both P<0.0001). At month 12, a significantly greater proportion of patients had a BCVA letter score ≥15 and BCVA letter score level >73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P<0.001). Health-related quality of life, assessed through National Eye Institute Visual Function Questionnaire (NEI VFQ-25), improved significantly from baseline with ranibizumab alone and combined with laser (P<0.05 for composite score and vision-related subscales) versus laser. Patients received ∼7 (mean) ranibizumab/sham injections over 12 months. No endophthalmitis cases occurred. Increased intraocular pressure was reported for 1 patient each in the ranibizumab arms. Ranibizumab monotherapy or combined with laser was not associated with an increased risk of cardiovascular or cerebrovascular events in this study. CONCLUSIONS: Ranibizumab monotherapy and combined with laser provided superior visual acuity gain over standard laser in patients with visual impairment due to DME. Visual acuity gains were associated with significant gains in VFQ-25 scores. At 1 year, no differences were detected between the ranibizumab and ranibizumab + laser arms. Ranibizumab monotherapy and combined with laser had a safety profile in DME similar to that in age-related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,428
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0493 · Cited by 720
Self-citationThe 14-year incidence of visual loss in a diabetic population,
Moss, S. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)96025-0 · Cited by 672
(2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.015 · Cited by 548
Treatment Techniques and Clinical Guidelines for Photocoagulation of Diabetic Macular Edema
(1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33527-4 · Cited by 544
Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
Nguyen, Q. D., Shah, S. M., Khwaja, A. A., Channa, R., Hatef, E., Do, D. V., Boyer, D., Heier, J. S., Abraham, P., Thach, A. B., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.08.016 · Cited by 532
How Does Visual Impairment Affect Performance on Tasks of Everyday Life?: The SEE Project
West, S. K. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.774 · Cited by 482
Klein, R., Knudtson, M. D., Lee, K. E., Gangnon, R., & Klein, B. E. K. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.016 · Cited by 415
(2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2008.610 · Cited by 398
Chia, E.-M., Wang, J. J., Rochtchina, E., Smith, W., Cumming, R. R., & Mitchell, P. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0661 · Cited by 316
Self-citationTen-year Incidence of Visual Loss in a Diabetic Population
Moss, S. E., Klein, R., & Klein, B. E. K. (1994) · Ophthalmology · doi:10.1016/s0161-6420(94)31217-6 · Cited by 196
Sun~er, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., & Bressler, N. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3225 · Cited by 170
Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population?
Owen, C. G., Rudnicka, A. R., Smeeth, L. L., Evans, J. R., Wormald, R., & FLETCHER, A. E. (2006) · BMC Ophthalmology · doi:10.1186/1471-2415-6-24 · Cited by 81
Diabetic retinopathy: a growing concern in an aging population.
Paulus, Y. M., & Gariano, R. F. (2009) · PubMed · Cited by 64
How consistent are health utility values?
Ferreira, P. L., Ferreira, L. N., & Pereira, L. N. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9368-8 · Cited by 42
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
Metadata
- Authors
- Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., & Weichselberger, A.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 118
- Issue
- 4
- Pages
- 615-625
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2161279821
- Cited by
- 1,326
- References
- 19
- FWCI
- 84.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.